scholarly journals Angiotensin Receptor Blockers Worsen Renal Function and Dyspnea on Ticagrelor: A Potential Ticagrelor-Angiotensin Receptor Blocker Interaction?

2012 ◽  
Vol 35 (11) ◽  
pp. 647-648 ◽  
Author(s):  
James J. DiNicolantonio ◽  
Victor L. Serebruany
Keyword(s):  
Renal Function ◽  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Receptor Blockers ◽  
Blocker Interaction

scholarly journals Angiotensin receptor blocker telmisartan: efficacy, safety and relevance of clinical application

2017 ◽  
Vol 14 (1) ◽  
pp. 51-57
Author(s):  
M L Maksimov ◽  
O V Dralova
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Disorders ◽  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Pressure Control ◽  
Antihypertensive Efficacy ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Cardiovascular Morbidity And Mortality ◽  
Receptor Blockers

Angiotensin receptor blocker telmisartan is a modern and effective antihypertensive drug which has advantages in comparison with other drugs of the group of angiotensin receptor blockers. Long half-life retains its effect is significant more than 24 hours, which is especially important for blood pressure control in the dangerous morning hours. Telmisartan is excreted by the kidneys less than 2%, making its use safe in patients with renal pathology. High antihypertensive efficacy combined with its excellent tolerability. Telmisartan has the greatest affinity to PPARg-receptors, which is especially important when selecting antihypertensive therapy in patients with arterial hypertension and metabolic disorders, insulin resistance, metabolic disorders. A considerable number of studies showing the effectiveness of treatment with telmisartan in patients with cardiovascular disease, diabetes, metabolic syndrome, nephropathy. The article presents the results of a study of therapeutic equivalence of generic drug is telmisartan, which showed a high bioequivalence to original brand-name formulation and was according to the indications: hypertension and decrease cardiovascular morbidity and mortality in patients aged 55 years and older with a high risk of cardiovascular disease. The results of our observations show comparable antihypertensive efficacy of the original and generic products and well tolerated by the results of questioning of patients.

scholarly journals Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension

2018 ◽  
Vol 2 (1) ◽  
pp. 100
Author(s):  
Megha Sood ◽  
Jagminder Kaur Bajaj ◽  
Jagminder Kaur Bajaj
Keyword(s):  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Oral Treatment ◽  
Treatment Options ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Treatment Of Hypertension ◽  
Receptor Blockers ◽  
Artery Disease ◽  
Azilsartan Medoxomil

Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.

Post-exercise Hypotension Produced by Supramaximal Interval Exercise is Potentiated by Angiotensin Receptor Blockers

2019 ◽  
Vol 40 (12) ◽  
pp. 756-761
Author(s):  
Miguel Ramirez-Jimenez ◽  
Felix Morales-Palomo ◽  
Juan Fernando Ortega ◽  
Ricardo Mora-Rodriguez
Keyword(s):  
Blood Pressure ◽  
Antihypertensive Medication ◽  
Angiotensin Receptor Blocker ◽  
Angiotensin Receptor Blockers ◽  
Blood Pressure Reduction ◽  
Angiotensin Receptor ◽  
Post Exercise ◽  
Interval Exercise ◽  
Receptor Blockers ◽  
Blood Pressure Responses

AbstractWe studied the effects of supramaximal interval exercise (SIE) with or without antihypertensive medication (AHM) on 21-hr blood pressure (BP) response. Twelve hypertensive patients chronically medicated with AHM, underwent three trials in a randomized order: a) control trial without exercise and substituting their AHM with a placebo (PLAC); b) placebo medicine and a morning bout of SIE (PLAC+SIE), and c) combining AHM and exercise (AHM+SIE). Acute and ambulatory blood pressure responses were measured for 21-hr after treatment. 20  min after treatment, systolic blood pressure (SBP) readings were reduced, similar to readings after PLAC+SIE (−9.7±6.0 mmHg, P<0.001) and AHM+SIE (−10.4±7.9 mmHg, P=0.001). 21 h after treatment, SBP remained reduced after PLAC+SIE (125±12 mmHg, P=0.022) and AHM+SIE (122±12 mmHg, P=0.013) compared to PLAC (132±16 mmHg). The BP reduction in PLAC+SIE faded out at 4 a.m., while in AHM+SIE it continued overnight. At night, BP reduction was larger in AHM+SIE than PLAC+SIE (–5.6±4.0 mmHg, P=0.006). Our data shows that a bout of supramaximal aerobic interval exercise in combination with ARB medication in the morning elicits a sustained blood pressure reduction lasting at least 21-h. Thus, the combination of exercise and angiotensin receptor blocker medication seems superior to exercise alone for acutely decreasing blood pressure.

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Peritoneal Dialysis: Systematic Review and Meta-Analysis of Randomized Controlled Trials

2009 ◽  
Vol 29 (5) ◽  
pp. 554-561 ◽  
Author(s):  
Ayub Akbari ◽  
Greg Knoll ◽  
Dean Ferguson ◽  
Brendan McCormick ◽  
Alexandra Davis ◽  
...  
Keyword(s):  
Renal Function ◽  
Outcome Measures ◽  
Enzyme Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Controlled Trials ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Randomized Controlled ◽  
Receptor Blockers

Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely used in clinical practice. The safety and efficacy of these agents in peritoneal dialysis (PD) patients are unclear. Objectives We conducted a systematic review to study the safety and efficacy of ACEI and ARB use in PD patients. Primary outcome measures were mortality and cardiovascular (CV) events; secondary outcome measures were renal function, proteinuria, hyperkalemia, and erythropoietin requirement at 3 months. Methods We searched Medline, EMBASE, Cochrane Central Register of Controlled Trials, trial registry Web sites, reference lists of eligible and review articles, as well as abstracts from the American Society of Nephrology and Canadian Society of Nephrology meetings. To be eligible, studies had to be randomized controlled trials that allocated PD patients to ACEI and ARB use or to placebo or other antihypertensive medications, included adult patients, and reported on at least one of the outcome measures. Results 418 citations were identified. Four met the eligibility criteria. Three examined CV events and mortality, of which two studies did not have any events. The third showed no statistically significant difference between control and treatment groups in either CV events or mortality: odds ratio 1.56 [95% confidence interval (CI) 0.24 – 10.05] for mortality and odds ratio 1.00 (95% CI 0.19 – 5.40) for CV events. Two studies reported renal function at 12 months and the weighted mean difference was 0.91 mL/minute/1.73 m2 (95% CI 0.14 – 1.68), favoring ACEI and ARB use. Conclusions In PD patients, evidence for the use of ACEIs and ARBs for reduction of mortality and CV events is lacking. Limited data suggest that they slow the loss of residual renal function.

scholarly journals Effects of Angiotensin Receptor Blocker on Oxidative Stress and Cardio-Renal Function in Streptozotocin-Induced Diabetic Rats

2009 ◽  
Vol 32 (8) ◽  
pp. 1411-1416 ◽  
Author(s):  
Wawaimuli Arozal ◽  
Kenichi Watanabe ◽  
Punniyakoti Thanikachalam Veeraveedu ◽  
Meilei Ma ◽  
Rajarajan Amirthalingam Thandavarayan ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Renal Function ◽  
Angiotensin Receptor Blocker ◽  
Diabetic Rats ◽  
Receptor Blocker ◽  
Angiotensin Receptor
Sign in / Sign up

Export Citation Format

Share Document